nach oben

Current Hematologic Malignancy Reports

Erschienen in:

16.05.2023

A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment

verfasst von: Josephine Anne Lucero, Jeffrey H. Lipton

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Long-term outcomes have significantly improved with treatment of chronic myeloid leukemia. With proper treatment, most patients will achieve similar survival rates compared to an age-matched population. Treatment-free remission is not attainable for over half of patients and chronic treatment carries with it unique challenges. We provide a pragmatic approach to the monitoring and management of chronic adverse effects (AEs).

Recent Findings

In the presence of severe or intolerable AEs, switching tyrosine kinase inhibitors (TKIs) is reasonable but is not without risk. Dose reductions can be attempted when response is stable to reduce AE intensity. More frequent molecular monitoring with any change is essential.

Summary

Treatment strategies must adapt to the personalized treatment goal of each patient. Long-term survival remains good even when response is less than a complete molecular response. Consider risks of new AEs when changing therapy and evaluate for dose reductions when appropriate.

Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC, editors. Williams hematology. 10th ed. New York: McGraw-Hill; 2021.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. https://doi.org/10.1038/s41375-020-0776-2.CrossRefPubMedPubMedCentral

Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen Y-B, Neuberg DS, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119:2620–9. https://doi.org/10.1002/cncr.28106.CrossRefPubMed

Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7. https://doi.org/10.1182/blood-2011-08-358135.CrossRefPubMedPubMedCentral

Vener C, Rossi S, Minicozzi P, Marcos-Gragera R, Poirel HA, Maynadié M, et al. Clear improvement in real-world chronic myeloid leukemia survival: a comparison with randomized controlled trials. Front Oncol. 2022;12:892684. https://doi.org/10.3389/fonc.2022.892684.CrossRefPubMedPubMedCentral

Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–93. https://doi.org/10.1016/S2352-3026(15)00048-4.CrossRefPubMedPubMedCentral

Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. American J Hematol. 2023;ajh.26836. https://doi.org/10.1002/ajh.26836.

Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, et al. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol. 2016;97:387–92. https://doi.org/10.1111/ejh.12743.CrossRefPubMed

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. JCO. 2016;34:2851–7. https://doi.org/10.1200/JCO.2015.66.2866.CrossRef

10.

Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood. 2015;126:1584–1584. https://doi.org/10.1182/blood.V126.23.1584.1584.CrossRef

11.

Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102–12. https://doi.org/10.1038/s41375-020-0867-0.CrossRefPubMedPubMedCentral

12.

Cortes J, Rea D, Lipton JH. Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors. Am J Hematol. 2018;ajh.25342. https://doi.org/10.1002/ajh.25342.

13.

Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option. Blood Rev. 2022;100968–100968. https://doi.org/10.1016/j.blre.2022.100968.

14.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529–31. https://doi.org/10.1038/leu.2017.247.CrossRefPubMedPubMedCentral

15.•

Stagno F, Breccia M, Di Raimondo F. On the road to treatment-free remission in chronic myeloid leukemia: what about ‘the others’? Expert Rev Anticancer Ther. 2020;20:1075–81. https://doi.org/10.1080/14737140.2020.1829483. Provides strategies on ongoing treatment of patients in stable MMR.CrossRefPubMed

16.

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18:1385–415. https://doi.org/10.6004/jnccn.2020.0047.CrossRef

17.

Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012;10:S-1-S−13. https://doi.org/10.6004/jnccn.2012.0184.CrossRef

18.

World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. n.d.

19.

Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez H, Van Le H, et al. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts. Drug Saf. 2017;40:317–31. https://doi.org/10.1007/s40264-016-0491-0.CrossRefPubMedPubMedCentral

20.

Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4:211–9. https://doi.org/10.1177/2042098613490780.CrossRefPubMedPubMedCentral

21.

Caldemeyer LE, Dugan MJ, Edwards JR, Edwards JG, Akard LP. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:71–9. https://doi.org/10.1007/s11899-016-0309-2.CrossRefPubMed

22.

Steegmann JL, Steegmann JL, Baccarani M, Baccarani M, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71. https://doi.org/10.1038/leu.2016.104.CrossRefPubMedPubMedCentral

23.

Patel AB, Wilds BW, Deininger MW. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? Expert Rev Hematol. 2017;10:659–74. https://doi.org/10.1080/17474086.2017.1330144.CrossRefPubMed

24.

García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15:90. https://doi.org/10.1186/s13045-022-01309-0.CrossRefPubMedPubMedCentral

25.

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, et al. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020;34:2064–73. https://doi.org/10.1038/s41375-020-0805-1.CrossRefPubMedPubMedCentral

26.

Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016;3:e581–91. https://doi.org/10.1016/S2352-3026(16)30167-3.CrossRefPubMed

27.

Ibrahim A, Moukalled N, Mahfouz R, El Cheikh J, Bazarbachi A, Abou DI. Safety and efficacy of elective switch from nilotinib to imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Hematol Int. 2022;4:30–4. https://doi.org/10.1007/s44228-022-00001-x.CrossRefPubMedPubMedCentral

28.

Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? Haematologica. 2019;104:862–4. https://doi.org/10.3324/haematol.2018.214445.CrossRefPubMedPubMedCentral

29.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, et al. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Ann Hematol. 2019;98:2329–38. https://doi.org/10.1007/s00277-019-03767-y.CrossRefPubMed

30.

Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, et al. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res. 2014;38:1173–6. https://doi.org/10.1016/j.leukres.2014.06.020.CrossRefPubMed

31.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, et al. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging. 2013;30:629–37. https://doi.org/10.1007/s40266-013-0088-6.CrossRefPubMed

32.

Park SJ, Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118:219–21. https://doi.org/10.1159/000111777.CrossRefPubMed

33.••

Cervantes F, Correa J-G, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, et al. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol. 2017;96:81–5. https://doi.org/10.1007/s00277-016-2839-z. Imatinib dose reduction is safe in sustained DMR.CrossRefPubMed

34.

Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2010;362:2251–9. https://doi.org/10.1056/NEJMoa0912614.CrossRefPubMed

35.••

Rea D. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a Real Life Observational Study (NILO-RED). Blood. 2017;130(Suppl_1):318. https://doi.org/10.1182/blood.V130.Suppl_1.318.318. Nilotinib once daily dosing is safe and feasible.CrossRef

36.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, et al. Frontline dasatinib treatment in a “real-life” cohort of patients older than 65 years with chronic myeloid leukemia. Neoplasia. 2016;18:536–40. https://doi.org/10.1016/j.neo.2016.07.005.CrossRefPubMedPubMedCentral

37.••

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67–75. https://doi.org/10.1002/cncr.32504. Low dose dasatinib frontline is safe and effective.CrossRefPubMed

38.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. JCO. 2016;34:2333–40. https://doi.org/10.1200/JCO.2015.64.8899.CrossRef

39.

Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S. Elderly patients with chronic myeloid Leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017;17:370–4. https://doi.org/10.1016/j.clml.2017.02.023.CrossRefPubMed

40.

Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8:e902–11. https://doi.org/10.1016/S2352-3026(21)00333-1.CrossRefPubMed

41.••

Rousselot P, Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194:393–402. https://doi.org/10.1111/bjh.17654. Use of therapeutic drug monitoring is beneficial to reduce AEs.CrossRefPubMed

42.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol. 2018;97:95–100. https://doi.org/10.1007/s00277-017-3144-1.CrossRefPubMed

43.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. JCO. 2018;36:231–7. https://doi.org/10.1200/JCO.2017.74.7162.CrossRef

44.

Castagnetti F, Gugliotta G, Bocchia M, Trawinska MM, Capodanno I, Bonifacio M, et al. Dose Optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019;134:496–496. https://doi.org/10.1182/blood-2019-127514.CrossRef

45.••

Kota V, Brümmendorf TH, Gambacorti-Passerini C, Lipton JH, Kim D-W, An F, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. Leukemia Res. 2021;111:106690. https://doi.org/10.1016/j.leukres.2021.106690. Bosutinib dose reduction is effective to reduce AEs.CrossRef

46.••

Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–50. https://doi.org/10.1182/blood.2021012082. Dose adjustments in response to monitoring is safe and effective.CrossRefPubMedPubMedCentral

47.

US Food and Drug Administration. FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia 2021.

48.

US Food and Drug Administration. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.

49.

Efficace F, Rosti G, Aaronson NK, Cottone F, Angelucci E, Molica S, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99:788–93. https://doi.org/10.3324/haematol.2013.093724.CrossRefPubMedPubMedCentral

50.

Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res. 2013;37:206–13. https://doi.org/10.1016/j.leukres.2012.10.021.CrossRefPubMed

51.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554–60. https://doi.org/10.1182/blood-2011-04-347575.CrossRefPubMed

52.

Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HSL, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097–103. https://doi.org/10.1007/s00520-012-1630-5.CrossRefPubMed

53.

Efficace F, Cottone F. Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia. Expert Rev Hematol. 2019;12:1–3. https://doi.org/10.1080/17474086.2019.1547189.CrossRefPubMed

Titel: A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment
verfasst von: Josephine Anne Lucero
Jeffrey H. Lipton
Publikationsdatum: 16.05.2023
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 4/2023
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-023-00698-4

Neu im Fachgebiet Onkologie

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

26.03.2025
Nierenkarzinom
Nachrichten

Seit wenigen Wochen ist mit Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor.

Warum genderspezifische Medizin notwendig ist

26.03.2025
FOKO 2025
Kongressbericht

Laut Zahlen der WHO aus dem Jahr 2024 sterben zwei Frauen pro Minute an Krankheiten, die mit geschlechtsspezifischen Faktoren zusammenhängen. Außerdem wirken Medikamente bei ihnen oft anders als bei Männern. Zeit für ein genderspezifisches Denken in der Medizin.

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

25.03.2025
Ösophaguskarzinom
Nachrichten

Studienziel erreicht, dennoch viele Fragen offen. So lassen sich die Ergebnisse der SANO-Studie zur Active-Surveillance versus sofortigen Ösophagektomie nach neoadjuvanter Komplettremission zusammenfassen. Interessant sind die Daten so oder so.

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

25.03.2025
FOKO 2025
Kongressbericht

Etwa 40 % der Frauen mit Mammakarzinom in Deutschland erkranken nach dem 70. Lebensjahr. Dennoch sind ältere Patientinnen in klinischen Studien häufig unterrepräsentiert. Wie können Betroffene optimal behandelt werden, ohne sie zu übertherapieren oder ihnen durch eine Untertherapie Chancen zu nehmen?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 4/2023

Neu im Fachgebiet Onkologie

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

Warum genderspezifische Medizin notwendig ist

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

Warum genderspezifische Medizin notwendig ist

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

Update Onkologie